The consensus is, therefore, that CKD screening should consist of dual assessment, in clinical practice most often measured by the eGFR and damage to the kidney structure, characterized by increased albuminuria, that is, the urinary albumin-to-creatinine ratio (UACR) [11]. This evidence concerns the gene ALB and chronic kidney disease.